Search research articles
Contact Us
Filters
Showing results (31-40 of 50) with videos related to
Page
of 5
Sort By:
Leukemia
|
February 22, 2024
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
Ekaterina Chelysheva, Jane Apperley, Anna Turkina, et al.
Lancet (London, England)
|
December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J Morgan, Faith E Davies, Walter M Gregory, et al.
American Journal of Hematology
|
July 12, 2025
Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Yishan Ye, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Nigel H Russell, Abin Thomas, Robert K Hills, et al.
The Lancet. Oncology
|
July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J Morgan, J Anthony Child, Walter M Gregory, et al.
Bone Marrow Transplantation
|
November 12, 2024
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Matjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, et al.
Blood Advances
|
October 6, 2021
Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting
Maria A V Marzolini, Varun Mehra, Kirsty J Thomson, et al.
British Journal of Haematology
|
March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results
Graham H Jackson, Gareth J Morgan, Faith E Davies, et al.
British Journal of Haematology
|
February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019
Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Bone Marrow Transplantation
|
February 16, 2022
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT
Joanna Drozd-Sokołowska, Luuk Gras, Nienke Zinger, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 50) with videos related to
Sort By:
Page
of 5
Leukemia
|
February 22, 2024
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
Ekaterina Chelysheva, Jane Apperley, Anna Turkina, et al.
Lancet (London, England)
|
December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J Morgan, Faith E Davies, Walter M Gregory, et al.
American Journal of Hematology
|
July 12, 2025
Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Yishan Ye, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Nigel H Russell, Abin Thomas, Robert K Hills, et al.
The Lancet. Oncology
|
July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J Morgan, J Anthony Child, Walter M Gregory, et al.
Bone Marrow Transplantation
|
November 12, 2024
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Matjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, et al.
Blood Advances
|
October 6, 2021
Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting
Maria A V Marzolini, Varun Mehra, Kirsty J Thomson, et al.
British Journal of Haematology
|
March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results
Graham H Jackson, Gareth J Morgan, Faith E Davies, et al.
British Journal of Haematology
|
February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019
Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Bone Marrow Transplantation
|
February 16, 2022
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT
Joanna Drozd-Sokołowska, Luuk Gras, Nienke Zinger, et al.
Page
of 5